AstraZeneca: Retaining Current Regulatory Procedures Crucial, Post-Brexit


Stephan Rau said that a major drug maker’s announced £275 million investment in three manufacturing sites in England and Scotland was good news for the UK and the pharma industry as a whole. “It is good to see that a company like [this] still decides to make significant investments in the UK despite Brexit, which will likely cut off the UK from the European market,” he added.